Stock Earnings
Satsuma Pharmaceuticals (STSA) Topples 75% on Thursday after Failing to Obtain Desired EMERGE efficacy Trial Results
Satsuma’s STS101 did not achieve statistical significance on the co-primary endpoints in Phase 3 EMERGE trials after which STSA plunged almost 76%. The moment Satsuma
